Br J Cancer 2007, 96:639–645.PubMedCrossRef 23. Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B: Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer. Clin Breast Cancer 2011, 11:129–134.PubMedCrossRef 24. Izawa A, Kobayashi D, Nasu S, Saito K, Moriai R, Asanuma K, Nakamura M, Yagihashi A, Watanabe N: Relevance of c-erbB-2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer. Anticancer Res 2002, 22:2965–2969.PubMed 25. Kennedy SM, O’Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O’Higgins NJ, Parkinson

M, Linehan R, Clynes M: Prognostic importance of survivin in breast cancer. Br J Cancer 2003, 88:1077–1083.PubMedCrossRef 26. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y, Feng Y: Quisinostat in vitro Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 2006, 107:746–756.PubMedCrossRef

27. Grunewald TG, Butt E: The LIM and SH3 domain protein AG-881 family: structural proteins or signal transducers or both? Mol Cancer 2008, 7:31.PubMedCrossRef 28. Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, Zimmer M, Butt E: Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res 2006, EPZ015666 purchase 312:974–982.PubMedCrossRef

29. Grunewald TG, Kammerer U, Winkler C, Schindler D, Sickmann A, Honig A, Butt E: Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localization. Br J Cancer 2007, 96:296–305.PubMedCrossRef 30. Traenka C, Remke M, Korshunov A, Bender S, Hielscher T, Northcott PA, Witt H, Ryzhova M, Felsberg J, Benner A, Riester S, Scheurlen W, Grunewald TG, von Deimling A, Kulozik AE, Reifenberger G, Taylor MD, Lichter P, Butt E, Pfister SM: Role of LIM and Amisulpride SH3 Protein 1 (LASP1) in the metastastic dissemination of medulloblastoma. Cancer Res 2010, 70:8003–8014.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions CW performed the miRNA, siRNA and plasmid transfection, the reporter gene construction, the luciferase experiments and drafted the manuscript. XQZ performed the western blot experiments. CYS performed the qRT-PCR. YRS performed colony formation assay and the migration assay. All authors read and approved the final manuscript.”
“Introduction An alarming rate of increase in the incidence of non-melanoma skin cancer (NMSC) is observed worldwide [1]. Within the United States itself, it has been estimated that about 1.7 million new cases of all forms of skin cancer are expected to be diagnosed each year [2].